Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02397499 · ClinicalTrials.gov registry record · Phase 3

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat

A Phase 3 study, sponsored by Neothetics.

Completed
Registry status
Phase 3
Development phase
800
Enrollment target

NCT02397499: Completed Phase 3 study, sponsored by Neothetics.

NCT02397499 is a Phase 3 study that has completed, run by Neothetics. The registered enrollment target is 800 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02397499, a Phase 3 study, has completed, sponsored by Neothetics.

COMPLETED
Registry status
Phase 3
Development phase
800 participants
Enrollment target

Study Summary

This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

Primary Outcome

Physical examination, adverse events, vital signs, and laboratory tests.

Interventions

  • DRUG Placebo
  • DRUG LIPO-202

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2015-04
Phase Phase 3
Neothetics

9 total trials

What the finished NCT02397499 record still lists

NCT02397499 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02397499 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02397499 about?

NCT02397499 is a clinical study titled "Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat". This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

What is the current status of trial NCT02397499?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2015-04.

What interventions are being tested in trial NCT02397499?

The interventions under investigation include: Placebo (DRUG), LIPO-202 (DRUG).

Who is sponsoring clinical trial NCT02397499?

This trial is sponsored by Neothetics, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02397499's enrollment target sits among peer trials

800 414th of 2000 higher than 1,573 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02397499, the US trial registry maintained by the National Library of Medicine. NCT02397499 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.